CA3036594C - Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof - Google Patents

Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof Download PDF

Info

Publication number
CA3036594C
CA3036594C CA3036594A CA3036594A CA3036594C CA 3036594 C CA3036594 C CA 3036594C CA 3036594 A CA3036594 A CA 3036594A CA 3036594 A CA3036594 A CA 3036594A CA 3036594 C CA3036594 C CA 3036594C
Authority
CA
Canada
Prior art keywords
alkyl
mmol
pyrazole
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3036594A
Other languages
English (en)
French (fr)
Other versions
CA3036594A1 (en
Inventor
Xiangyang Chen
Yingxiang GAO
Norman Xianglong Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of CA3036594A1 publication Critical patent/CA3036594A1/en
Application granted granted Critical
Publication of CA3036594C publication Critical patent/CA3036594C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3036594A 2016-09-19 2017-01-25 Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof Active CA3036594C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610833890.3A CN107840842A (zh) 2016-09-19 2016-09-19 炔代杂环化合物、其制备方法及其在医药学上的应用
CN201610833890.3 2016-09-19
PCT/CN2017/072570 WO2018049781A1 (zh) 2016-09-19 2017-01-25 炔代杂环化合物、其制备方法及其在医药学上的应用

Publications (2)

Publication Number Publication Date
CA3036594A1 CA3036594A1 (en) 2018-03-22
CA3036594C true CA3036594C (en) 2024-02-13

Family

ID=61618562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3036594A Active CA3036594C (en) 2016-09-19 2017-01-25 Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof

Country Status (12)

Country Link
US (3) US10710981B2 (enExample)
EP (1) EP3517535B1 (enExample)
JP (1) JP6906811B2 (enExample)
KR (1) KR102783517B1 (enExample)
CN (2) CN107840842A (enExample)
AU (1) AU2017327954B2 (enExample)
CA (1) CA3036594C (enExample)
ES (1) ES2925212T3 (enExample)
MX (1) MX390747B (enExample)
RU (1) RU2729069C1 (enExample)
SG (1) SG10202102822RA (enExample)
WO (1) WO2018049781A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894403A1 (en) 2018-12-13 2021-10-20 Intervet International B.V. Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220120638A (ko) * 2019-12-26 2022-08-30 베이징 이노케어 파마 테크 씨오., 엘티디. (s)-1-(1-아크릴로일피롤리딘-3-일)-3-((3,5-디메톡시페닐)에티닐)-5-(메틸아미노)-1h-피라졸-4-카르복사미드의 결정질 형태
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023528880A (ja) * 2020-06-05 2023-07-06 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
BR112022024729A2 (pt) * 2020-06-05 2023-02-28 Kinnate Biopharma Inc Inibidores de quinases do receptor do fator de crescimento de fibroblastos
CN115867547B (zh) * 2020-08-27 2024-12-20 上海和誉生物医药科技有限公司 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用
EP4277903A4 (en) * 2021-01-12 2024-11-27 Beijing InnoCare Pharma Tech Co., Ltd. PROCESS FOR PREPARING (S)-1-(1-ACRYLOYLPYRROLIDIN-3-YL)-3-((3,5-DIMETHOXYPHENYL)ETHINYL)-5-(METHYLAMINO)-1H-PYRAZOL-4-CARBOXAMIDE
CN115433190B (zh) * 2021-06-02 2024-09-20 药雅科技(上海)有限公司 不可逆杂环化合物fgfr抑制剂的制备方法和用途
CN114853739B (zh) * 2021-02-03 2023-09-22 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN115043832B (zh) * 2021-03-08 2023-08-22 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
MX2024005341A (es) * 2021-11-03 2024-05-20 Beijing Innocare Pharma Tech Co Ltd Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida.
KR20240107172A (ko) * 2021-11-16 2024-07-08 베이징 이노케어 파마 테크 씨오., 엘티디. 두경부암을 치료하는 방법
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
MX2024006933A (es) * 2021-12-08 2024-08-26 Kinnate Biopharma Inc Formas en estado solido de un inhibidor de fgfr.
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
CN1508130A (zh) 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
US7150894B2 (en) * 2003-05-01 2006-12-19 Kraft Foods Holdings, Inc. Acid whey texture system
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007059341A2 (en) 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
ES2364864T3 (es) * 2006-12-21 2011-09-15 Astrazeneca Ab Acilaminopirazoles como inhibidores de fgfr.
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
UA105005C2 (uk) * 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
EP2736514B1 (en) * 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
WO2013024427A1 (en) 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
PT3023100T (pt) * 2013-07-18 2019-05-29 Taiho Pharmaceutical Co Ltd Fármaco antitumoral para administração intermitente de inibidor de fgfr
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PE20160546A1 (es) 2013-10-25 2016-05-26 Novartis Ag Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
US10189813B2 (en) 2015-03-25 2019-01-29 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Also Published As

Publication number Publication date
CN107840842A (zh) 2018-03-27
CN109843873A (zh) 2019-06-04
SG10202102822RA (en) 2021-05-28
MX390747B (es) 2025-03-21
JP2019529444A (ja) 2019-10-17
US20210332027A1 (en) 2021-10-28
JP6906811B2 (ja) 2021-07-21
KR102783517B1 (ko) 2025-03-19
CN109843873B (zh) 2022-06-17
AU2017327954B2 (en) 2022-02-03
US20190210997A1 (en) 2019-07-11
KR20190052113A (ko) 2019-05-15
AU2017327954A1 (en) 2019-05-02
RU2729069C1 (ru) 2020-08-04
CA3036594A1 (en) 2018-03-22
US10710981B2 (en) 2020-07-14
US20200339541A1 (en) 2020-10-29
WO2018049781A1 (zh) 2018-03-22
US11059805B2 (en) 2021-07-13
EP3517535B1 (en) 2022-06-29
EP3517535A1 (en) 2019-07-31
MX2019003143A (es) 2019-06-17
US11572353B2 (en) 2023-02-07
ES2925212T3 (es) 2022-10-14
EP3517535A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CA3036594C (en) Alkynyl-substituted heterocyclic compound, preparation method thereof and medical use thereof
JP6966590B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
ES2605388T3 (es) Compuesto inhibidor de Trk
CN107922387B (zh) Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用
CN105934432A (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP2373657A1 (en) 5, 7-dihydro- 6h-pyrimido ý 5, 4-d¨ý 1¨benzazepin-6-thiones as plk inhibitors
JP2017502092A (ja) ヘテロアリール及びその使用
CN115490671B (zh) Parp7抑制剂及其制备方法
FR2941948A1 (fr) Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
EP2411389A2 (fr) DERIVES D'AZACARBOLINES 9H-PYRROLO[2,3-b:5,4-c']DIPYRIDINE, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE
RU2709810C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-с]ПИРИДИНА
ES2391371T3 (es) Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el HDL-colesterol
CA2730071A1 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
JP2023515729A (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
KR20150047134A (ko) Ｎ-［２-（｛２-［（２Ｓ）-２-시아노피롤리딘-１-일］-２-옥소에틸｝아미노）-２-메틸프로필］-２-메틸피라졸로［１, ５-ａ］피리미딘-６-카르복사미드의 결정
CA3244518A1 (en) Substituted fused cyclic compound, associated pharmaceutical composition, preparation process and associated uses
CN103492371A (zh) 含有螺环的二氢吡唑类化合物
CN110272416A (zh) 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用
TWI727152B (zh) 炔代雜環化合物、其製備方法及其在醫藥學上的應用
HK40002345B (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
HK40002345A (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
HK40089264A (zh) 用作cdk7激酶抑制剂的化合物及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

EEER Examination request

Effective date: 20220112

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219